Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Exploring the possibility of treating SCD in-utero with novel gene-editing technology

Panicos Shangaris, LRCP&SI, MBBCh, BAO, PhD, King’s College London, London, UK, shares some insights into research exploring the possibility of using a novel gene-editing tool to treat sickle cell disease (SCD) in-utero, which may provide an off-the-shelf product for those with a fetus affected by SCD. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.